2	§ 100602. Invention and Licensing Reporting Requirements.
3	(a) Prior to an NGA and continuing 12 months after the close of a Grant, a Grantee must
4	have written agreements with Grantee Personnel and Collaborators requiring prompt disclosure
5	to the Grantee of any CIRM-Funded Invention.
6	(b) Within 60 calendar days after a CIRM-Funded Invention has been disclosed to a
7	Grantee, the Grantee must notify CIRM of the CIRM-Funded Invention through the use of the
8	CIRM Invention Disclosure Form, which will be received in confidence by CIRM. The
9	Invention Disclosure Form shall identify the Grant under which the CIRM-Funded Invention was
10	made, the Inventor(s) and the Principle Investigator. The Disclosure shall be sufficiently
11	complete in technical detail to convey a clear understanding, to the extent known at the time of
12	the disclosure, of the nature, purpose, operation, and physical, chemical, biological or electrical
13	characteristics of the CIRM-Funded Invention. If the CIRM-Funded Invention has been
14	submitted for publication or presentation, then the Disclosure shall identify the publication, the
15	date of the abstract or manuscript or presentation, the submission date and if relevant any
16	publication dates, including publication via the internet.
17	(c) Within 60 calendar days after a Grantee executes an exclusive license agreement,
18	non-exclusive license agreement, material transfer agreement, research collaboration agreement,
19	or any other agreement conveying rights in CIRM-Funded Inventions or CIRM-Funded
20	Technology, a Grantee shall notify CIRM of the execution of such agreement(s) and submit to
21	CIRM a copy of the executed agreement. The notification and agreement(s) shall be marked
22	"Confidential" in accordance with Health and Safety Code section 125290.30, subdivision
23	(e)(2)(B).
١	10/05/12 1 OAL Notice

Amend 17 Cal. Code of Regs. section 100602 to read:

1	(de) A Grantee must	submit annually to CIRM during,	and for 15 years after, the Project
2	Period of the Grant, an Inve	ntion Utilization Report containing	g the following information:
3	(1) Grantees must re	port all patent applications filed w	hich claim, or cite to publications
4	concerning, CIRM-Funded	Inventions, including the countries	in which application(s) were filed
5	application serial number(s)	, status and detailed description(s)	of the CIRM-Funded Invention(s)
6	and		
7	(2) Grantees must re	port the issuance or abandonment	of any patent applied for that
8	claims, or cites to publicatio	ns concerning, CIRM-Funded Inve	ention, including the patent
9	number and date of issuance	or abandonment and the countries	s in which the applications have
10	issued or have been abandor	ned; and	
11	(3) Grantees must re	port the total funding from all sour	ces that directly contributed to a
12	CIRM-Funded Invention dis	closed or claimed in the patent app	plication, including each co-
13	funder's identity, the dollar	amounts each contributed and the	dates of contribution. CIRM may
14	audit all such co-funding rep	ports; and	
15	(4) A Grantee must r	eport to CIRM the execution of all	Exclusive License Agreements,
16	Non-Exclusive License Agre	eements, Material Transfer Agreen	nents or Collaborative Agreements
17	conveying rights in CIRM-F	unded Inventions or CIRM-Funde	d Technology; and
18	(5) In the event that a	a CIRM- Funded Invention or CIR	M-Funded Technology generates
19	revenue or other consideration	on (whether from a License Agreer	ment or otherwise), a Grantee
20	must report such revenue or	consideration received during the	preceding 12 month period or
21	since the last report, whicher	ver is longer.	
22	(6) A Grantee must	report the following key progress t	oward commercialization of a
23	CIRM-Funded Invention or	CIRM-Funded Technology includi	ing the following:
	10/05/12	2	OAL Notice

1	(A) Initiation of clinical testing;
2	(B) Initiation of pivotal studies; and
3	(C) Application for marketing approval.
4	(7) Grantee shall have written agreements with its Grantee Personnel, Collaborators,
5	licensees and transferees requiring such third parties to report to the Grantee information
6	described in this subdivision (de).
7	(ed) The Invention Utilization Report shall be marked "Confidential" in accordance with
8	Health and Safety Code section 125290.30, subdivision (e)(2)(B).
9	(fe) CIRM reserves the right to itself and its agents to conduct an audit of the Grantee and
10	Collaborators to ensure compliance with this Chapter. Grantee and Collaborators must maintain
11	and provide such documentation as is necessary to establish compliance. Further, Grantee must
12	ensure that its Collaborators, Grantee Personnel and all Exclusive and Non-Exclusive Licensees
13	maintain such documentation as is necessary to establish compliance.
14	Note: Authority cited: Article XXXV, California Constitution; Section 125290.40(j), Health and
15	Safety Code. Reference: Section 125290.30, Health and Safety Code.